Nutrition 21

Diabetes, obesity, metabolic syndrome, cardiovascular disease and depression caused by poor insulin function

The history of Nutrition21 started as Applied Microbiology, Inc in 1983 with the intention to develop therapeutics for infectious diseases. As the company’s focus deflected to the development of nutritional supplements followed by the presentation of their first dietary product (Cardia Salt®), it changed its name to AMBI INC. in 1996. In 1997, AMBI Inc. acquired Nutrition 21, a privately held partnership in San Diego, California. The California partnership was founded in 1973 and launched Selenomax®, an organic selenium, yeast one year later. In 2001, AMBI INC.changed its name to Nutrition 21, Inc. Current reasearch in collaborations and alliances with Comprehensive NeuroScience, Duke University Medical Center, Warneford Hospital at Oxford University, University of Vermont College of Medicine, Penn State University and the Harvard University School of Public Health.

Gerard Butler and Michael Fink, interim Co-Chief Executive Officers
Alan J. Kirschbaum, CFO

John H. Gutfreund
P. George Benson, Ph.D
John L. Cassis
Warren D. Cooper, M.D.
Audrey T. Cross, Ph.D
Peter C. Mann
Marvin Moser, M.D.
Paul S. Intlekofer

4 Manhattanville Road
Purchase, New York 10577
USA
Phone: +1-914-701-4500

Nutrition 21’s science is mainly focused on chromium, a trace mineral essential in its role as a co-factor of insulin. Between 1959 and 1977, initial observations in people with type 2 diabetes, or diabetes mellitus, led researchers to hypothesise that chromium picolinate, which is Nutrition 21’s form of chromium, might benefit individuals who have insulin resistant diabetes. Clinical studies involving over 1500 subjects were carried out and the results demonstrated that supplemental use of the company’s chromax chromium picolinate, at 200 to 1000 mcg has an ability to improve glycemic control in people with or at risk for diabetes.
Nutrition 21 owns approximately 38 patents, some are listed below.

The company has numerous ongoing clinical trials.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.